Fall Clinical (FC), 2025

Bimekizumab rates of oral candidiasis in patients with moderate to severe plaque psoriasis: Results from up to 4 years of five phase 3/3b studies

Real-World Dosing Patterns of Biologics for the Treatment of Hidradenitis Suppurativa

Bimekizumab impact on flare in hidradenitis suppurativa over 2 years: Data from BE HEARD EXT

Bimekizumab clinical efficacy responses translate into improvements in patient outcomes to Week 48 in patients with moderate to severe hidradenitis suppurativa: Results from BE HEARD I&II

Bimekizumab long-term efficacy in patients with plaque psoriasis from BE BRIGHT: Improvements in mean absolute clinical outcome scores over 4 years

Real-World Clinician- and Patient-Reported Outcomes and Treatment Persistence Following Bimekizumab Initiation in Patients with Psoriasis: 6-Month Results from the PPD CorEvitas Psoriasis Registry